Guo Feiying, Zhong Huajie, Wu Yuan, Xu Xue, Tan Jiarong, Zhou Qiang, Tang Shunli
Department of Dermatology, Huzhou Central Hospital, Fifth School of Clinical Zhejiang Chinese Medical University, Huzhou, China.
Department of Dermatology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, China.
Front Med (Lausanne). 2025 Feb 5;12:1485079. doi: 10.3389/fmed.2025.1485079. eCollection 2025.
Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4/13 receptor chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA.
苔藓样淀粉样变（LA）是原发性皮肤淀粉样变（PCA）的一种亚型，其特征为伴有剧烈瘙痒的角化过度丘疹，目前缺乏标准化治疗。度普利尤单抗是一种靶向白细胞介素（IL）-4/13受体α链的人源单克隆抗体，广泛应用于2型炎症性疾病的治疗。本文报告了2例用度普利尤单抗成功治疗的难治性LA病例，并回顾了有关度普利尤单抗治疗PCA的文献报道。
